1
|
Stucky A, Gao L, Li SC, Tu L, Luo J, Huang X, Chen X, Li X, Park TH, Cai J, Kabeer MH, Plant AS, Sun L, Zhang X, Zhong JF. Molecular Characterization of Differentiated-Resistance MSC Subclones by Single-Cell Transcriptomes. Front Cell Dev Biol 2022; 10:699144. [PMID: 35356283 PMCID: PMC8959432 DOI: 10.3389/fcell.2022.699144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 02/14/2022] [Indexed: 11/25/2022] Open
Abstract
Background: The mechanism of tumorigenicity potentially evolved in mesenchymal stem cells (MSCs) remains elusive, resulting in inconsistent clinical application efficacy. We hypothesized that subclones in MSCs contribute to their tumorgenicity, and we approached MSC-subclones at the single-cell level. Methods: MSCs were cultured in an osteogenic differentiation medium and harvested on days 12, 19, and 25 for cell differentiation analysis using Alizarin Red and followed with the single-cell transcriptome. Results: Single-cell RNA-seq analysis reveals a discrete cluster of MSCs during osteogenesis, including differentiation-resistant MSCs (DR-MSCs), differentiated osteoblasts (DO), and precursor osteoblasts (PO). The DR-MSCs population resembled cancer initiation cells and were subjected to further analysis of the yes associated protein 1 (YAP1) network. Verteporfin was also used for YAP1 inhibition in cancer cell lines to confirm the role of YAP1 in MSC--involved tumorigenicity. Clinical data from various cancer types were analyzed to reveal relationships among YAP1, OCT4, and CDH6 in MSC--involved tumorigenicity. The expression of cadherin 6 (CDH6), octamer-binding transcription factor 4 (OCT4), and YAP1 expression was significantly upregulated in DR-MSCs compared to PO and DO. YAP1 inhibition by Verteporfin accelerated the differentiation of MSCs and suppressed the expression of YAP1, CDH6, and OCT4. A survey of 56 clinical cohorts revealed a high degree of co-expression among CDH6, YAP1, and OCT4 in various solid tumors. YAP1 inhibition also down-regulated HeLa cell viability and gradually inhibited YAP1 nuclear localization while reducing the transcription of CDH6 and OCT4. Conclusions: We used single-cell sequencing to analyze undifferentiated MSCs and to discover a carcinogenic pathway in single-cell MSCs of differentiated resistance subclones.
Collapse
Affiliation(s)
- Andres Stucky
- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, CA, United States
| | - Li Gao
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Shengwen Calvin Li
- Neuro-oncology and Stem Cell Research Laboratory, CHOC Children’s Research Institute, Center for Neuroscience Research, Children’s Hospital of Orange County (CHOC), Orange, CA, United States
- Department of Neurology, Irvine School of Medicine, University of California, Irvine, CA, United States
- *Correspondence: Shengwen Calvin Li, ; Lan Sun, ; Xi Zhang,
| | - Lingli Tu
- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, CA, United States
- Department of Oncology, Bishan, The People’s Hospital of Bishan District, Bishan, Chongqing, China
| | - Jun Luo
- Stomatological Hospital of Chongqing Medical University, Chongqing, China
| | - Xi Huang
- Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xuelian Chen
- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, CA, United States
| | - Xiaoqing Li
- Department of Oncology, Bishan, The People’s Hospital of Bishan District, Bishan, Chongqing, China
| | - Tiffany H. Park
- School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Jin Cai
- Department of Oral and Maxillofacial Surgery, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China
| | - Mustafa H. Kabeer
- Pediatric Surgery, CHOC Children’s Hospital, Department of Surgery, Irvine School of Medicine, University of California, Irvine, CA, United States
| | - Ashley S. Plant
- Division of Pediatric Oncology, Children’s Hospital of Orange County, Orange, CA, United States
| | - Lan Sun
- Department of Oncology, Bishan, The People’s Hospital of Bishan District, Bishan, Chongqing, China
- *Correspondence: Shengwen Calvin Li, ; Lan Sun, ; Xi Zhang,
| | - Xi Zhang
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China
- *Correspondence: Shengwen Calvin Li, ; Lan Sun, ; Xi Zhang,
| | - Jiang F. Zhong
- Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, CA, United States
| |
Collapse
|
2
|
Plant AS, Pulley M, Di K, Goldsmith C, Pathare J, Muhonen M, Loudon WG, Olaya J, Bota D. THER-06. PROTEASOME INHIBITION IN PRIMARY MEDULLOBLASTOMA CELL CULTURE AND PATIENT-DERIVED XENOGRAFT MODELS: A POTENTIAL THERAPEUTIC IMPLICATION. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | - Kaijun Di
- University of California, Irvine, Irvine, CA, USA
| | | | - Jody Pathare
- Children’s Hospital Orange County, Orange, CA, USA
| | | | | | - Joffre Olaya
- Children’s Hospital Orange County, Orange, CA, USA
| | - Daniela Bota
- University of California, Irvine, Irvine, CA, USA
| |
Collapse
|
3
|
Li SC, Stucky A, Chen X, Kabeer MH, Loudon WG, Plant AS, Torno L, Nangia CS, Cai J, Zhang G, Zhong JF. Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel. Oncotarget 2018; 9:33290-33301. [PMID: 30279960 PMCID: PMC6161791 DOI: 10.18632/oncotarget.26044] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 08/13/2018] [Indexed: 12/12/2022] Open
Abstract
The clinical benefits of the MammaPrint® signature for breast cancer is well documented; however, how these genes are related to cell cycle perturbation have not been well determined. Our single-cell transcriptome mapping (algorithm) provides details into the fine perturbation of all individual genes during a cell cycle, providing a view of the cell-cycle-phase specific landscape of any given human genes. Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel derived its clinical prognosis power from measuring the cell cycle activity of specific breast cancer samples. Such cell cycle phase index of the MammaPrint® signature suggested that measurement of the cell cycle index from tumors could be developed into a prognosis tool for various types of cancer beyond breast cancer, potentially improving therapy through targeting a specific phase of the cell cycle of cancer cells.
Collapse
Affiliation(s)
- Shengwen Calvin Li
- Neuro-oncology and Stem Cell Research Laboratory, CHOC Children's Research Institute, Children's Hospital of Orange County; Department of Neurology, University of California-Irvine School of Medicine, Orange, CA, USA
| | - Andres Stucky
- Division of Periodontology, Diagnostic Sciences and Dental Hygiene, and Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA
| | - Xuelian Chen
- Division of Periodontology, Diagnostic Sciences and Dental Hygiene, and Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA
| | - Mustafa H. Kabeer
- Pediatric Surgery, CHOC Children's Hospital, Department of Surgery, University of California-Irvine School of Medicine, Orange, CA, USA
| | - William G. Loudon
- Neuroscience Institute, Children's Hospital of Orange County (CHOC), Gamma Knife Center of Southern California, Department of Neurosurgery, University of California-Irvine School of Medicine, Orange, CA, USA
| | - Ashley S. Plant
- Division of Pediatric Oncology, Children's Hospital of Orange County, Orange, CA, USA
| | - Lilibeth Torno
- Hyundai Cancer Institute at CHOC Children's Hospital, Oncology, Bone and Soft Tissue Tumor Program, After Cancer Treatment Survivorship Program, CHOC Children's Hospital, Orange, CA, USA
| | - Chaitali S. Nangia
- Chan Soon-Shiong Institute for Medicine, Verity Medical Foundation, Laguna Hills, CA, USA
| | - Jin Cai
- Department of Oral and Maxillofacial Surgery, Zhuhai People's Hospital, Zhuhai, China
| | - Gang Zhang
- Department of Oral and Maxillofacial Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Jiang F. Zhong
- Division of Periodontology, Diagnostic Sciences and Dental Hygiene, and Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
4
|
Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, Plant AS, Su HC, Allenspach EJ, Slatter M, Abinun M, Lilic D, Cunningham-Rundles C, Eckstein O, Olbrich P, Guillerman RP, Patel NC, Demirdag YY, Zerbe C, Freeman AF, Holland SM, Szabolcs P, Gennery A, Torgerson TR, Milner JD, Leiding JW. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol 2018; 142:1665-1669. [PMID: 30092289 DOI: 10.1016/j.jaci.2018.07.020] [Citation(s) in RCA: 171] [Impact Index Per Article: 28.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Revised: 07/09/2018] [Accepted: 07/24/2018] [Indexed: 12/16/2022]
Affiliation(s)
- Lisa R Forbes
- Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Tex; Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex.
| | - Tiphanie P Vogel
- Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Tex; Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex
| | - Megan A Cooper
- Department of Pediatrics, Division of Rheumatology, Washington University, St Louis, Mo
| | - Johana Castro-Wagner
- Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, St Petersburg, Fla
| | - Edith Schussler
- Division of Allergy and Immunology and Department of Medicine and Pediatrics, The Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Katja G Weinacht
- Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, Calif
| | - Ashley S Plant
- Department of Pediatric Oncology, Children's Hospital of Orange County, Orange, Calif
| | - Helen C Su
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Eric J Allenspach
- Division of Rheumatology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, Wash
| | - Mary Slatter
- Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation and Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, United Kingdom
| | - Mario Abinun
- Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation and Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, United Kingdom
| | - Desa Lilic
- Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation and Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, United Kingdom
| | - Charlotte Cunningham-Rundles
- Division of Allergy and Immunology and Department of Medicine and Pediatrics, The Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Olive Eckstein
- Department of Hematology and Oncology, Texas Children's Cancer Center, Houston, Tex
| | - Peter Olbrich
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md; Department of Pediatric Infectious Diseases and Immunopathologies, Institute of Biomedicine Seville (IBiS), University Hospital Virgen del Rocio, Seville, Spain
| | - R Paul Guillerman
- Department of Pediatric Radiology, Texas Children's Hospital and Department of Radiology, Baylor College of Medicine, Houston, Tex
| | - Niraj C Patel
- Department of Pediatrics, Section of Infectious Disease and Immunology, Levine Children's Hospital, Atrium Health, Charlotte, NC
| | - Yesim Y Demirdag
- Department of Pediatrics, Division of Pediatric Allergy and Immunology, College of Physcians and Surgeons of Columbia Univeristy, New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY
| | - Christa Zerbe
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Alexandra F Freeman
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Steven M Holland
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Paul Szabolcs
- Division of Blood and Marrow Transplantation and Cellular Therapies, University of Pittsburgh, Pittsburgh, Pa
| | - Andrew Gennery
- Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation and Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, United Kingdom
| | - Troy R Torgerson
- Division of Rheumatology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, Wash
| | - Joshua D Milner
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Jennifer W Leiding
- Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, St Petersburg, Fla; Cancer and Blood Disorders Institute, Johns Hopkins-All Children's Hospital, St Petersburg, Fla.
| |
Collapse
|
5
|
Plant AS, Ma C, Shyr D, Lee MA, Chi SN. MBCL-10. TREATMENT OUTCOMES AND COMPLICATION RATES OF SINGLE VERSUS TANDEM AUTOLOGOUS TRANSPLANT FOR REGIMENS FOR MEDULLOBLASTOMA. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - Clement Ma
- Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Derek Shyr
- Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard T.H. Can School of Public Health, Boston, MA, USA
| | - Michelle A Lee
- Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Susan N Chi
- Dana-Farber Cancer Institute, Boston, MA, USA
| |
Collapse
|
6
|
Plant AS, Pathare J, Engelhart D, Williams V, Kirov I, Loudon WG. NSRG-17. GAMMA KNIFE RADIOSURGERY FOR THE TREATMENT OF GRADE I AND II ASTROCYTOMAS IN THE PEDIATRIC POPULATION. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - Jody Pathare
- Children’s Hospital Orange County, Orange, CA, USA
| | | | | | - Ivan Kirov
- Children’s Hospital Orange County, Orange, CA, USA
| | | |
Collapse
|
7
|
Plant AS, Pathare J, Engelhart D, Williams V, Kirov I, Loudon WG. NSRG-14. SAFETY AND EFFICACY OF GAMMA KNIFE RADIOSURGERY FOR PEDIATRIC BRAIN TUMORS. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Jody Pathare
- Children’s Hospital Orange County, Orange, CA, USA
| | | | | | - Ivan Kirov
- Children’s Hospital Orange County, Orange, CA, USA
| | | |
Collapse
|
8
|
Mochizuki AY, Frost IM, Mastrodimos MB, Plant AS, Wang AC, Moore TB, Prins RM, Weiss PS, Jonas SJ. Precision Medicine in Pediatric Neurooncology: A Review. ACS Chem Neurosci 2018; 9:11-28. [PMID: 29199818 PMCID: PMC6656379 DOI: 10.1021/acschemneuro.7b00388] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Central nervous system tumors are the leading cause of cancer related death in children. Despite much progress in the field of pediatric neurooncology, modern combination treatment regimens often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, secondary malignancies, and a host of other chronic health problems. Precision medicine strategies applied to pediatric neurooncology target specific characteristics of individual patients' tumors to achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we review emerging trends and the current literature that have guided the development of new molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and delivery platforms for the treatment of pediatric central nervous system tumors.
Collapse
Affiliation(s)
- Aaron Y. Mochizuki
- Department
of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Isaura M. Frost
- Department
of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Melina B. Mastrodimos
- Department
of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Ashley S. Plant
- Division
of Pediatric Oncology, Children’s Hospital of Orange County, Orange, California 92868, United States
| | - Anthony C. Wang
- Department
of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Theodore B. Moore
- Department
of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Robert M. Prins
- Department
of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
- Jonsson
Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
- Department
of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States
| | - Paul S. Weiss
- California
NanoSystems Institute, University of California, Los Angeles, Los Angeles, California 90095, United States
- Department
of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095, United States
- Department
of Materials Science and Engineering, University of California, Los Angeles, Los
Angeles, California 90095, United States
- Jonsson
Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Steven J. Jonas
- California
NanoSystems Institute, University of California, Los Angeles, Los Angeles, California 90095, United States
- Department
of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States
- Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, California 90095, United States
- Children’s
Discovery and Innovation Institute, University of California, Los Angeles, Los
Angeles, California 90095, United States
| |
Collapse
|
9
|
Plant AS, Koyama S, Sinai C, Solomon IH, Griffin GK, Ligon KL, Bandopadhayay P, Betensky R, Emerson R, Dranoff G, Kieran MW, Ritz J. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol 2018; 137:269-278. [DOI: 10.1007/s11060-017-2737-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 12/29/2017] [Indexed: 01/07/2023]
|
10
|
Plant AS, Koyama S, Sinai C, Solomon I, Griffin G, Betensky R, Emerson R, Dranoff G, Kieran MW, Ritz J. IMMU-23. IMMUNOPHENOTYPING OF PEDIATRIC BRAIN TUMORS: CORRELATING IMMUNE INFILTRATE WITH HISTOLOGY, MUTATIONAL LOAD, AND SURVIVAL AND ASSESSING CLONAL T CELL RESPONSE. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Plant AS, Chi SN, Frazier L. Pediatric malignant germ cell tumors: A comparison of the neuro-oncology and solid tumor experience. Pediatr Blood Cancer 2016; 63:2086-2095. [PMID: 27554756 DOI: 10.1002/pbc.26165] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 06/30/2016] [Accepted: 07/01/2016] [Indexed: 12/11/2022]
Abstract
Malignant germ cell tumors (GCT) arise from abnormal migration of primordial germ cells and are histologically identical whether they occur inside or outside the central nervous system (CNS). However, the treatment strategy for GCTs varies greatly depending on the location of the tumor. These differences are in part due to the increased morbidity of surgery in the CNS but may also reflect differential sensitivity of the tumors to chemotherapy and radiation therapy (RT) or not-yet-understood biologic differences between these tumors. Historically, specialists caring for extracranial and intracranial GCT in the United States have practiced separately without much cross communication. The focus of this review is a discussion of differences between the management of CNS and extra-CNS GCTs and opportunities for collaboration and future research.
Collapse
Affiliation(s)
- Ashley S Plant
- Pediatric Hematology/Oncology, Brain Tumors Center, Dana Farber Cancer Institute, Boston, Massachusetts.
| | - Susan N Chi
- Pediatric Hematology/Oncology, Solid Tumor Center, Dana Farber Cancer Institute, Boston, Massachusetts
| | - Lindsay Frazier
- Pediatric Hematology/Oncology, Brain Tumors Center, Dana Farber Cancer Institute, Boston, Massachusetts
| |
Collapse
|
12
|
Plant AS, Venick RS, Farmer DG, Upadhyay S, Said J, Kempert P. Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients. Pediatr Blood Cancer 2013; 60:E137-9. [PMID: 23813867 DOI: 10.1002/pbc.24632] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Accepted: 05/09/2013] [Indexed: 11/12/2022]
Abstract
Post-transplant lymphoproliferative disease (PTLD) is a lymphoproliferative disorder secondary to chronic immunosuppression and is the most common malignancy in transplanted patients [Kamdar et al. Curr Opin Organ Transplant, 2011; 16:274-280]. Although PTLD usually presents as B or T cell lymphoma, plasmacytomas have been reported, mostly in the adult population. Six cases of pediatric plasmacytoma-like PTLD have been reported, all of which were treated with vincristine, adriamycin, and dexamethasone (VAD), high dose dexamethasone alone, or dexamethasone + thalidomide [Tcheng et al. Pediatric Blood Cancer, 2006; 47:218-223; Perry et al. Blood, 2013; 8:1377-1383]. We present two cases of pediatric plasmacytoma-like PTLD in combined liver and small bowel transplant patients both successfully treated with bortezomib and dexamethasone based on multiple myeloma protocols [Kyle and Rajkumar, Clin Lymphoma Myeloma, 2009; 9:278-288; Adams and Kaufmann, Cancer Invest, 2004; 22:304-311].
Collapse
Affiliation(s)
- Ashley S Plant
- Department of Pediatrics, Division of Hematology/Oncology, Los Angeles, California
| | | | | | | | | | | |
Collapse
|